he start of the collaboration was announced earlier this spring, so the press release comes as no surprise, although the agreement announced now provides a concrete indication of the first steps of the collaboration. According to the release, the collaboration at this stage includes the use of Aiforia's AI solutions in the analysis of tissue samples from prostate cancer patients and the use of Aiforia's AI model development software.

Aiforia's revenue growth stalled in the first half of the year, particularly in the US, although recent months’ customer wins suggest that the company is continuing to capture the market.

Fimlab Laboratories Ltd, Finland's largest healthcare technology company, has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions.

The regional health management of Castilla y León in Spain has chosen Aiforia as its partner for AI-based diagnostics. The collaboration involves the use of selected Aiforia AI solutions for the analysis of tissue samples, e.g., from breast, prostate, and lung cancer patients.

With the 10 MEUR share issue last week, Aiforia’s financial situation strengthened. In light of positive sales news, the company seems to continue moving toward a strong position in its rapidly emerging markets, although weak growth predictability still argues for certain caution in pricing the potential. However, we still find the risk/reward ratio of the company’s promising long-term growth story attractive.